Perrigo Company
PRGO
Source: the SEC Form 13F filings of the managers we follow, latest for Q2 2026. How we use them
Value held
$4.7m
Combined value at quarter end
Last quarter
1 bought
0 sold or trimmed
Price at Q3 ’25 end
$22.27
-16.7% in the quarter
Share price change by quarter
-7.6%Q4 ’19
-16.9%Q3 ’20
-2.6%Q4 ’20
+9.1%Q1 ’25
-4.7%Q2 ’25
-16.7%Q3 ’25
Managers holding it, by quarter
0Q4 ’23
1Q1 ’24
2Q2 ’24
2Q3 ’24
2Q4 ’24
2Q1 ’25
2Q2 ’25
3Q3 ’25
0Q4 ’25
0Q1 ’26
1Q2 ’26
0Q3 ’26
Who holds it
| Maverick Capital | 0.0%$4.7m | New |
About the company
- Sector
- Health care · Pharmaceutical Preparations
- Incorporated in
- Ireland
- Financial year ends
- 31 December
- Shares outstanding
- 139m at 31 Jul 2026
- SEC filings
- Annual reports and other filings on EDGAR
Revenue and profit
$3.9bnJun ’14
$4.2bnJun ’15
$5.3bn2016
$4.9bn2017
$4.7bn2018
$3.9bn2019
$4.1bn2020
$4.1bn2021
$4.5bn2022
$4.7bn2023
$4.4bn2024
$4.3bn2025
| Year | Revenue | Net income |
|---|---|---|
| 2025 | $4.3bn | −$1.4bn |
| 2024 | $4.4bn | −$172m |
| 2023 | $4.7bn | −$12.7m |
| 2022 | $4.5bn | −$141m |
| 2021 | $4.1bn | −$68.9m |
| 2020 | $4.1bn | −$163m |
| 2019 | $3.9bn | $146m |
| 2018 | $4.7bn | $131m |
| 2017 | $4.9bn | $120m |
| 2016 | $5.3bn | −$4.0bn |
| Year to Jun 2015 | $4.2bn | $136m |
| Year to Jun 2014 | $3.9bn | $233m |